Recruiting
Phase 2

Estrogen

Sponsor:

Université de Montréal

Code:

NCT00315107

Conditions

Acromegaly

Eligibility Criteria

Sex: Female

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Alesse

Study Details

Brief summary:

Oral estrogens may be an effective adjuvant treatment for control of acromegaly in patients with resistance to somatostatin analogs.

Conditions

Acromegaly

Study ID

NCT00315107

Start date

May, 2006

Status verified date

May, 2006

Completion date

Aug, 2007

Eligibility Criteria

Eligibility Criteria

Sex: Female

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Women 18 years and older treated with somatostatin analogs
  • Active acromegaly

Exclusion Criteria:

  • Cardiovascular or cerebrovascular disease
  • Thrombophlebitis or thromboembolism
  • Breast cancer
  • Non-controlled arterial hypertension
  • Smoking
  • Pregnancy or lactation

Study Design

Enrollment

30 participants

Allocation

Randomized

Intervention Model

Parallel Assignment

Interventions and Outcome Measures

Interventions

Alesse

Central Contacts and Locations

Central contacts

Omar SERRI, MD

514-890-8000omar.serri@umontreal.ca

Locations

CHUM - Notre-Dame Hospital

Recruiting

Montreal, Quebec, Canada, H2L 4M1

Principal Investigator:

Omar Serri, MD

More Information

Sponsor

Université de Montréal

Last update posted

May 26, 2006

Last verified

May, 2006

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Université de Montréal on 2006-05-26.